AAIPharma and Cortria Corp. have signed a deal granting Cortria the right to use AAIPharma’s proprietary, controlled release oral drug delivery technology known as ProCR in conjunction with Cortria’s TRIA-662 drug candidate.   ProCR is a novel controlled-release technology developed by AAIPharma for use with orally administered drug products. TRIA-662 is Cortria’s lead drug candidate, currently in Phase II clinical development for dyslipidemia. In preliminary human studies, TRIA-66...